SG11202009970VA - Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use - Google Patents

Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use

Info

Publication number
SG11202009970VA
SG11202009970VA SG11202009970VA SG11202009970VA SG11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA SG 11202009970V A SG11202009970V A SG 11202009970VA
Authority
SG
Singapore
Prior art keywords
antibodies
beta
methods
cross
latent tgf
Prior art date
Application number
SG11202009970VA
Inventor
Hideaki Shimada
Masakazu Kanamori
Xing'er Christine Koo
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11202009970VA publication Critical patent/SG11202009970VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
SG11202009970VA 2019-08-28 2020-08-28 Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use SG11202009970VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019155278 2019-08-28
PCT/JP2020/032522 WO2021039945A1 (en) 2019-08-28 2020-08-28 Cross-species anti-latent tgf-beta 1 antibodies and methods of use

Publications (1)

Publication Number Publication Date
SG11202009970VA true SG11202009970VA (en) 2021-04-29

Family

ID=74684250

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009970VA SG11202009970VA (en) 2019-08-28 2020-08-28 Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use

Country Status (18)

Country Link
US (2) US11312767B2 (en)
EP (1) EP4021498A4 (en)
JP (2) JP6846564B2 (en)
KR (2) KR20220043930A (en)
CN (1) CN114729370A (en)
AR (1) AR120077A1 (en)
AU (1) AU2020340176A1 (en)
BR (1) BR112022003412A2 (en)
CA (1) CA3149151A1 (en)
CL (1) CL2022000438A1 (en)
CO (1) CO2022001789A2 (en)
CR (1) CR20220125A (en)
IL (1) IL290816A (en)
MX (1) MX2022001938A (en)
PE (1) PE20221447A1 (en)
SG (1) SG11202009970VA (en)
TW (2) TWI737469B (en)
WO (1) WO2021039945A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220043930A (en) 2019-08-28 2022-04-05 추가이 세이야쿠 가부시키가이샤 Cross-species anti-latent tgf-beta 1 antibodies and methods of use
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005105144A1 (en) 2004-04-30 2007-09-13 協和醗酵工業株式会社 Latent TGF-β activation inhibitor
WO2011102483A1 (en) 2010-02-19 2011-08-25 独立行政法人理化学研究所 HUMAN LAP TGF-β BINDING ANTIBODY
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
JP2016500704A (en) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Compositions and methods for modulating cell signaling
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
MX2018003196A (en) * 2015-09-15 2019-05-16 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof.
SG11201807176XA (en) * 2016-03-11 2018-09-27 Scholar Rock Inc TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
AU2018205231A1 (en) 2017-01-06 2019-07-18 Scholar Rock, Inc. Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
JP2020186172A (en) 2017-06-19 2020-11-19 株式会社ボナック ANTI-TGF-β1 ANTIBODIES
CA3071427A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019045086A1 (en) * 2017-08-29 2019-03-07 林化成株式会社 USE FOR SPECIFIC ANTIBODY FOR ACTIVE OR LATENT TGF-β1
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3755723A4 (en) * 2018-02-23 2021-12-22 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
SG11202013231SA (en) 2018-07-11 2021-01-28 Scholar Rock Inc HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
WO2020160291A2 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
KR20220043930A (en) 2019-08-28 2022-04-05 추가이 세이야쿠 가부시키가이샤 Cross-species anti-latent tgf-beta 1 antibodies and methods of use
WO2022180764A1 (en) * 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies

Also Published As

Publication number Publication date
CA3149151A1 (en) 2021-03-04
KR102376605B1 (en) 2022-03-21
AR120077A1 (en) 2022-02-02
PE20221447A1 (en) 2022-09-21
IL290816A (en) 2022-04-01
TW202142571A (en) 2021-11-16
CN114729370A (en) 2022-07-08
BR112022003412A2 (en) 2022-05-24
MX2022001938A (en) 2022-03-11
EP4021498A1 (en) 2022-07-06
TW202122422A (en) 2021-06-16
US20220204605A1 (en) 2022-06-30
EP4021498A4 (en) 2024-01-03
KR20210039328A (en) 2021-04-09
CL2022000438A1 (en) 2022-11-25
TWI737469B (en) 2021-08-21
JP6846564B2 (en) 2021-03-24
CR20220125A (en) 2022-05-04
AU2020340176A1 (en) 2022-04-14
US20210395356A1 (en) 2021-12-23
CO2022001789A2 (en) 2022-06-10
JP2021118685A (en) 2021-08-12
US11312767B2 (en) 2022-04-26
WO2021039945A1 (en) 2021-03-04
JP2021036864A (en) 2021-03-11
KR20220043930A (en) 2022-04-05

Similar Documents

Publication Publication Date Title
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
EP3852805A4 (en) Anti-lilrb2 antibodies and methods of use thereof
IL290816A (en) Cross-species anti-latent tgf-beta 1 antibodies and methods of use
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL289829A (en) Immunomodulatory antibodies and methods of use thereof
EP3755723A4 (en) Cross-species anti-latent tgf-beta 1 antibodies and methods of use
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and their methods of use
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
EP3731867A4 (en) Anti-lrp5/6 antibodies and methods of use
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
IL291730A (en) Protein-macromolecule conjugates and methods of use thereof
EP3746484A4 (en) Anti-ms4a6a antibodies and methods of use thereof
EP4061848A4 (en) Anti-ror-2 antibodies and methods of use
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same